Transthyretin Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Transthyretin stocks.

Transthyretin Stocks Recent News

Date Stock Title
Nov 21 BBIO Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Nov 15 ABUS Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Nov 15 ABUS Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Transthyretin

Transthyretin (TTR or TBPA) is a transport protein in the serum and cerebrospinal fluid that carries the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol. This is how transthyretin gained its name: transports thyroxine and retinol. The liver secretes transthyretin into the blood, and the choroid plexus secretes TTR into the cerebrospinal fluid.
TTR was originally called prealbumin (or thyroxine-binding prealbumin) because it ran faster than albumin on electrophoresis gels.
Transthyretin protein is encoded by TTR gene located in the 18th chromosome.

Browse All Tags